SCHEMBL5514770

SCHEMBL5514770

Fc1ccc(COC2CCC3(CC2)OCCO3)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.46
PRMT6 Q96LA8 1/20 0.46
HDAC4 P56524 2/20 0.45
NAAA Q02083 1/20 0.43
OPRM1 P35372 2/20 0.40
OPRL1 P41146 2/20 0.40
DPP4 P27487 1/20 0.40
ALDH1A1 P00352 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
FFAR1 O14842 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
KCNH2 Q12809 1/20 0.38
SIGMAR1 Q99720 1/20 0.37
IDO1 P14902 1/20 0.37
AGXT P21549 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL720768 0.84 OPRM1 (0.56) CARM1PRMT6OPRM1OPRL1DPP4
SCHEMBL5524763 0.83 CARM1 (0.50) CARM1PRMT6OPRM1OPRL1DPP4
SCHEMBL5519299 0.79
SCHEMBL5515387 0.79 DPP4 (0.50) CARM1PRMT6HDAC4NAAAOPRM1
SCHEMBL10686275 0.79 OPRM1 (0.54) CARM1PRMT6OPRM1OPRL1DPP4
SCHEMBL17943011 0.77 CARM1 (0.55) CARM1PRMT6HDAC4NAAASLC6A2
SCHEMBL5521291 0.77 CARM1 (0.48) CARM1PRMT6OPRM1OPRL1DPP4
SCHEMBL5848185 0.76 TRPA1 (0.42) ALDH1A1L3MBTL1
SCHEMBL16839484 0.75 NAAA (0.54) CARM1PRMT6HDAC4NAAASLC6A2
SCHEMBL8990348 0.74 CARM1 (0.53) CARM1PRMT6NAAASIGMAR1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167452-A1 Therapeutic amide derivatives PFIZER, INC. 2007-07-19 US disclosed
US-20070167452-A1 Therapeutic amide derivatives PFIZER, INC. 2007-07-19 US disclosed
US-20070167452-A1 Therapeutic amide derivatives PFIZER, INC. 2007-07-19 US disclosed
EP-1716100-A2 THERAPEUTIC AMIDE DERIVATIVES Pfizer, Inc. (US) 2006-11-02 EP disclosed
WO-2005080317-A2 THERAPEUTIC AMIDE DERIVATIVES PFIZER JAPAN, INC. (JP) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167452-A1 Therapeutic amide derivatives GRIN1, GRIN2B, GRIN3A CARM1 1945/4885PRMT6 1988/4885HDAC4 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.